C12N 2760/16022
New viral proteins or individual genes, new structural or functional aspects of
Official title: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/16022 (New viral proteins or individual genes, new structural or functional aspects of) appears on 185 US grants and 214 published applications in this corpus.
Search patents in C12N- Granted patents
- 185
- Published applications
- 214
- Assignees
- 149
- Inventors
- 479
- Latest grant
- 13 Jan 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1979 | 1 | 0 |
| 1980 | 1 | 0 |
| 1981 | 0 | 0 |
| 1982 | 1 | 0 |
| 1983 | 0 | 0 |
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 1 | 0 |
| 1987 | 0 | 0 |
| 1988 | 1 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 3 | 0 |
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 3 | 0 |
| 1997 | 5 | 0 |
| 1998 | 7 | 0 |
| 1999 | 8 | 0 |
| 2000 | 6 | 0 |
| 2001 | 5 | 0 |
| 2002 | 8 | 5 |
| 2003 | 6 | 13 |
| 2004 | 6 | 9 |
| 2005 | 8 | 11 |
| 2006 | 6 | 5 |
| 2007 | 10 | 7 |
| 2008 | 4 | 5 |
| 2009 | 4 | 12 |
| 2010 | 4 | 14 |
| 2011 | 4 | 8 |
| 2012 | 0 | 8 |
| 2013 | 5 | 8 |
| 2014 | 3 | 5 |
| 2015 | 5 | 5 |
| 2016 | 9 | 16 |
| 2017 | 6 | 8 |
| 2018 | 5 | 10 |
| 2019 | 8 | 15 |
| 2020 | 7 | 5 |
| 2021 | 6 | 10 |
| 2022 | 8 | 8 |
| 2023 | 6 | 7 |
| 2024 | 4 | 11 |
| 2025 | 7 | 2 |
| 2026 | 1 | 7 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods of generating broadly protective vaccine compositions comprising neuraminidase13 Jan 2026US 12,521,430 B2Sanofi Pasteur Limited
- Engineered influenza antigenic polypeptides and immunogenic compositions thereof28 Oct 2025US 12,454,555 B2Sanofi Pasteur Limited
- Sindbis control virus24 Jun 2025US 12,338,463 B2LGC Clinical Diagnostics, Inc.
- FcRn-targeted mucosal vaccination against influenza infections13 May 2025US 12,297,233 B2University of Maryland, College Park
- Recombinant influenza viruses with stabilized HA for replication in eggs18 Mar 2025US 12,251,436 B2The University of Tokyo
- Method of producing negative-strand rna virus vector and produced negative-strand rna virus vector27 Aug 2026US 2026/0250709 A1Repli-Tech Co., Ltd.
- Influenza neuraminidase tetramers13 Aug 2026US 2026/0234589 A1Icosavax, Inc.
- Switchable mrna expression platform6 Aug 2026US 2026/0224679 A1
- Genetic enhancement of exosome production2 Jul 2026US 2026/0185108 A1The Johns Hopkins University
- Vaccine compositions and uses thereof9 Apr 2026US 2026/0097112 A1Centivax, Inc.
Most cited
By later US patents
- Recombinant negative strand RNA virus expression-systems218US 5,166,057 AMount Sinai School of Medicine of the City University of New York · 1992
- Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides190US 5,679,647 AThe Regents of the University of California · 1997
- Composition and methods for transfecting eukaryotic cells122US 5,578,475 ALife Technologies Corporation · 1996
- Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response111US 5,830,702 AThe Trustees of the University of Pennsylvania · 1998
- Method for treating allergic lung disease110US 5,849,719 AThe Regents of the University of California · 1998